Salute e Benessere

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From…

Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid' 2025 PARIS and CAMBRIDGE, Mass., Dec.04, 2023(GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment...
Nasdaq GlobeNewswire
04/12/2023

Inventiva announces the positive recommendation of the third DMC of the Phase…

The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety dataThe safety assessment was based on the review of safety data from more than 500 patients, including patients that have been treated with lanifibranor for more than 72 weeksThe DMC review remains consistent, confirming the good safety profile of lanifibranorDaix (France), Long Island City (New York, United States), December 4, 2023– Inventiva...
Nasdaq GlobeNewswire
04/12/2023

Medical Device First to Enter the European Market with Sustainable, Innovative…

ClorDiSys' method of chlorine dioxide gas generation was developed by Johnson and Johnson and produces a non-acidic gas that is gentle on materials. The process also does not result in harmful residues, which is a concern that is often experienced with ethylene oxide sterilization. A sterilization feature also highly of interest is that cycles do not require an increase in temperature as ethylene oxide requires. This allows temperature sensitive devices to be highly successful under chlorine…
PR Newswire
04/12/2023

Surgical Sutures Market Worth $5.5 Billion | MarketsandMarkets

Browse in-depth TOC on "Surgical Sutures Market" Browse in-depth TOC on "Surgical Sutures Market" 348 - Tables 52 - Figures 319 - Pages Surgical Sutures Market Scope: The hospital segment is expected to register a substantial share by end users of the Surgical Sutures market. Hospitals play a pivotal role as end users in the surgical suture market, holding a substantial share. This dominance is rooted in the extensive and diverse range of surgical procedures...
PR Newswire
04/12/2023

Ocular Drug Delivery Market to reach $115.5 Billion, Globally, by 2032 at 5.5%…

Request Sample of the Report on Ocular Drug Delivery Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/3646 Request Sample of the Report on Ocular Drug Delivery Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/3646 Prime determinants of growth Technological advancements in the ocular drug delivery, rise in number of people suffering from eye disorders, and increase in geriatric population drive the growth of the ocular drug...
PR Newswire
04/12/2023

Result of AGM

DXS INTERNATIONAL PLCResult of AGM The Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems is pleased to announce that at the Annual General Meeting held on 30 November, all resolutions were duly passed.The Directors of DXS International plc accept responsibility for this announcementEnquiries: David Immelman (Chief Executive)DXS International plc 01252...
Nasdaq GlobeNewswire
04/12/2023

Soaring Demand for Space-saving and Energy-efficient Ovens Drives Commercial…

The global commercial combi oven market value is forecasted to increase from US$ 2,321.0 million in 2023 to US$ 5,984.3 million by 2033. The demand for commercial combi ovens is projected to surge at a CAGR of 10.0% over the assessment period. The global commercial combi oven market value is forecasted to increase from US$ 2,321.0 millionin 2023to US$ 5,984.3 millionby 2033. The demand for commercial combi ovens is projected to surge at aCAGR of 10.0%over the assessment period...
PR Newswire
04/12/2023

Epinephrine Market Size Estimated to Reach USD 5,796.9 Million by 2032 |…

The Asia Pacific epinephrine market size was estimated at USD 651.3 million in 2022 and is estimated to surpass around USD 1,545.5 million by 2032, growing at a healthy CAGR of 9.1% 2023 to 2032. TheAsia Pacificepinephrine market size was estimated atUSD 651.3 millionin 2022 and is estimated to surpass aroundUSD 1,545.5 millionby 2032, growing at a healthy CAGR of 9.1% 2023 to 2032. The LAMEA epinephrine market size surpassed atUSD 329.7 millionin 2022 and is estimated to...
PR Newswire
04/12/2023

Contact Lens Solution Market to Hit US$2.78 Billion by 2034 as Fashion Accessory…

NEWARK, Del., Dec. 4, 2023 /PRNewswire/ -- The valuation for the global contact lens cleaning solution market was around US$ 1.75 billion in 2023. The market is projected to exhibit a CAGR of 4.3% over the forecast period. The global market value is estimated at US$ 1.83 billion in 2024 and will reach US$ 2.78 billion by 2034. NEWARK, Del.,Dec. 4, 2023/PRNewswire/ -- The valuation for the global contact lens cleaning solution market was aroundUS$ 1.75 billionin 2023. The market is...
PR Newswire
04/12/2023

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions - Pekka Jalovaara

BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 4 December 2023 at 4.45 p.m. (EET)BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara ____________________________________________Person subject to the notification requirementName: Jalovaara PekkaPosition: Member of the Board/Deputy memberIssuer: BBS Bioactive Bone Substitutes OyjLEI: 743700BYSBP0PCR6N767Notification type: INITIAL NOTIFICATIONReference number:...
Nasdaq GlobeNewswire
04/12/2023

Liquid Biopsy Market Size to Hit USD 29.8 billion by 2035, Registering at a CAGR…

The liquid biopsy market is anticipated to be worth USD 5.4 billion in 2023 and is expected to reach over USD 29.8 billion by 2035 at a compounded annual growth rate (CAGR) of 15.2% during the forecast period. The liquid biopsy market is anticipated to be worthUSD 5.4 billion in 2023 and is expected to reach overUSD 29.8 billion by 2035 at a compounded annual growth rate (CAGR) of 15.2% during the forecast period. Cancer has become the leading cause of death across the globe...
PR Newswire
04/12/2023

Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer…

Expanded strategic and operational leadership positions Zenas for growth as obexelimab advances in late-stage clinical trials for multiple potential I&I indications “We are thrilled to welcome Tanya and Jen to our executive team,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma. “Tanya is a deeply experienced physician-scientist leader and Jen is a seasoned healthcare finance and corporate development leader. With their decades of industry leadership...
Nasdaq GlobeNewswire
04/12/2023

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 04 December 2023– On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under…
Nasdaq GlobeNewswire
04/12/2023

Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davis, Chief Operating Officer and Chief Medical Officer will present at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, December 6th at 3:00 PM ET. The presentation will be focused on Tiziana's recent clinical updates and our Phase 2 trial of intranasal foralumab, a fully human...
Nasdaq GlobeNewswire
04/12/2023

OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to…

Top-line Efficacy and Safety Data on Track for Release in December 2023 LONDON and NEW YORK, Dec.04, 2023(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce the last patient of a planned 240-patient...
Nasdaq GlobeNewswire
04/12/2023

Veneered Panels Market revenue to hit USD 16.5 Billion by 2033, Says We Market…

Sustainability and eco-friendly practices have emerged as transformative factors within the veneered panels industry, positioning themselves as game-changers that significantly influence consumer choices, industry practices, and market dynamics. In an era where environmental consciousness is paramount, consumers and businesses alike are increasingly prioritizing products with sustainable attributes, and veneered panels are no exception. Sustainability and eco-friendly practices have emerged…
PR Newswire
04/12/2023

Infinium Global Research Reveals Insights on Healthcare Markets across Saudi…

More Insights on this report, Speak to Our Analyst: https://www.infiniumglobalresearch.com/contact-us More Insights on this report, Speak to Our Analyst:https://www.infiniumglobalresearch.com/contact-us Budget Healthcare Saudi Arabialeads healthcare spending among Gulf Cooperation Council (GCC) nations, contributing 60% of the total. The government prioritizes healthcare, with a reduced budget of$50.4 billion( SAR 189 billion ) in fiscal year 2023, representing a 4...
PR Newswire
04/12/2023

Digital Pathology Market to Exceed USD 2.3 billion by 2035, Due to the Growing…

The global digital pathology market size was estimated at USD 0.8 billion in 2023 and is expected to reach over USD 2.3 billion by 2035, growing at a CAGR of 8.4% in the forecast period 2023- 2035. The global digital pathology market size was estimated atUSD 0.8 billion in 2023 and is expected to reach overUSD 2.3 billion by 2035, growing at a CAGR of 8.4% in the forecast period 2023- 2035. Pathology refers to the branch of medical science that primarily emphasizes the causes,...
PR Newswire
04/12/2023

XNK Therapeutics to present at DNB Nordic Healthcare Conference in Oslo

For more information, please contact: Johan Liwing, CEO, XNK TherapeuticsTel: +46 706 70 36 75E-mail: johan.liwing@xnktherapeutics.com For more information, please contact: Johan Liwing, CEO, XNK Therapeutics Tel: +46 706 70 36 75 E-mail:johan.liwing@xnktherapeutics.com About XNK Therapeutics AB XNK Therapeutics is a clinical stage immunotherapy company focused on bringing new and more effective treatments to cancer patients. The company is at the forefront of autologous NK...
PR Newswire
04/12/2023

ALLCLEAR RESEARCH REVEALS OVER 55's VIEW HOLIDAYS AS AN IMPORTANT WELLBEING…

AllClear's survey of a representative sample of older holidaymakers (aged 55 or over) reveals there has been a big upturn in the percentage of people over 55 feeling they need an escape from the economic gloom (up from 23% to 40%), and a break to generally cheer themselves up (a rise from 32% to 44%). AllClear's survey of a representative sample of older holidaymakers (aged 55 or over) reveals there has been a big upturn in the percentage of people over 55 feeling they need an escape from the...
PR Newswire
04/12/2023

Nexstim Releases New System Functionalities for Research Use in Europe

Press release, Helsinki, 4 December 2023 at 10 AM (EET) Nexstim Releases New System Functionalities for Research Use in Europe Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has delivered its first research system module as part of Nexstim NBS (Navigated Brain Stimulation) System 5 with the new functionalities of paired pulse delivery and an EEG user interface. As the new module option is for research use only, it is not CE-marked or FDA cleared but can be used with a…
Nasdaq GlobeNewswire
04/12/2023

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in…

Novel ultra-high affinity ligand OncoFAP targets Fibroblast Activation Protein (FAP), associated with a variety of solid tumors Licensing agreement between Philochem and Blue Earth Diagnostics, one of the Bracco family of companies, encompasses applications of OncoFAP for diagnostic and medical imagingPhilogen's Phase I clinical trial with investigational68 Ga-OncoFAP is underway in Europe, with first three patients successfully imaged Blue Earth Diagnostics will assume...
Nasdaq GlobeNewswire
04/12/2023

Skin Cancer and Reconstructive Surgery Center of California Adopts AI-driven…

"SciBase and the SCARS Center team are well aligned with a shared mission to provide clinicians with early detection of melanoma solutions that can drive improved patient outcomes," said Pia Renaudin, CEO of SciBase. "We are continuing to broaden SciBase's presence throughout the US, to further increase patient access to point-of-care technology that enables the earliest detection possible of melanoma when it is almost 100% curable". "SciBase and the SCARS Center team…
PR Newswire
04/12/2023

87 000 Orion Corporation A shares converted into B shares

ORION CORPORATIONSTOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 4 DECEMBER 2023 at 9.45 EET 87 000 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 87 000 A shares have been converted into 87 000 B shares. The conversion has been entered into the Trade Register on 4 December 2023.The total number of shares in Orion Corporation is 141,134,278 which,...
Nasdaq GlobeNewswire
04/12/2023
Altri  Comunicati